📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
161 analysed today
FollowTelegram
161
Today
149,562
All-time analysed
42,894
Positive
6,654
Negative
91,341
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
113 announcements match the current filters (relevance ≥ 5).
Dr. Lal PathLabs Declares ₹3.5 Interim Dividend; Q3 Revenue Grows 10.6% YoY
Dr. Lal PathLabs has declared its third interim dividend of ₹3.5 per share for FY 2025-26, with the record date set for February 5, 2026. The company reported a 10.6% YoY increase in Q3 revenue to ₹6,598 million, though net profit for the quarter dipped to ₹914 million from ₹981 million in the previous year. This profit decline was primarily due to a one-time exceptional item of ₹301 million related to the impact of new labor codes. For the nine-month period, the company maintains a healthy growth trajectory with PAT rising 12.1% to ₹3,776 million.
Key Highlights
Declared 3rd interim dividend of ₹3.5 per equity share (35% of face value).
Q3 FY26 revenue from operations rose 10.6% YoY to ₹6,598 million.
Net profit for the quarter stood at ₹914 million, impacted by a ₹301 million exceptional charge.
9M FY26 revenue reached ₹20,602 million compared to ₹18,588 million in the previous year.
Record date for dividend eligibility is February 5, 2026, with payment within 30 days.
👀 What to Watch
Investors should view the profit dip as a one-time accounting adjustment rather than a business slowdown, given the double-digit revenue growth. The consistent dividend payout remains a positive sign for long-term income-seeking shareholders.
Dr. Lal PathLabs Q3 Revenue Grows 10.6% YoY to ₹6,598M; Declares ₹3.5 Interim Dividend
Dr. Lal PathLabs reported a 10.6% YoY increase in consolidated revenue for Q3 FY26, reaching INR 6,598 million. However, net profit for the quarter declined to INR 914 million from INR 981 million in the previous year, largely due to a one-time exceptional expense of INR 301 million related to labor code impacts. The company has declared a third interim dividend of INR 3.5 per share, maintaining its commitment to shareholder returns. While top-line growth remains healthy, margins were sequentially lower compared to the preceding quarter.
Key Highlights
Revenue from operations increased 10.6% YoY to INR 6,598 million in Q3 FY26.
Net profit (PAT) stood at INR 914 million, down from INR 981 million YoY due to a ₹301 million exceptional item.
Declared a 3rd interim dividend of INR 3.5 per equity share with a record date of February 5, 2026.
Total expenses rose to INR 5,298 million, driven by higher employee benefits and collection center fees.
Basic EPS for the quarter was INR 5.42, compared to INR 5.80 in the corresponding quarter of the previous year.
👀 What to Watch
Investors should focus on the resilient 10% revenue growth while monitoring the impact of rising operational costs on margins. The dividend payout provides a steady yield, but the sequential dip in performance suggests a cautious watch on volume growth in the coming quarters.
Kalpataru Reports 23% Growth in 9M Pre-Sales to ₹3,447 Cr; Q3 Pre-Sales Dip 14% YoY
Kalpataru Limited reported a mixed performance for Q3 FY26, with quarterly pre-sales declining by 14% YoY to ₹870 crore. However, the cumulative nine-month performance remains strong, with pre-sales growing 23% YoY to ₹3,447 crore. Collections showed robust growth, increasing 17% in Q3 to ₹1,101 crore and 30% for the nine-month period to ₹3,409 crore. The overall nine-month trajectory suggests healthy demand and improved cash flow despite a quarterly dip in sales bookings.
Key Highlights
9M FY26 pre-sales increased by 23% YoY to ₹3,447 crore from ₹2,807 crore
9M FY26 collections grew significantly by 30% YoY to ₹3,409 crore
Q3 FY26 pre-sales saw a 14% YoY decline, falling to ₹870 crore from ₹1,008 crore
Q3 FY26 collections remained strong at ₹1,101 crore, up 17% YoY from ₹943 crore
👀 What to Watch
Investors should focus on the strong cumulative nine-month growth and improved cash flow through collections rather than the quarterly sales dip. Monitor the upcoming full earnings report to understand the reasons behind the Q3 pre-sales decline.
Dr. Lal PathLabs Launches SOVAAKA Wellness Centre to Expand into Premium Preventive Care
Dr. Lal PathLabs has launched SOVAAKA, a premium wellness center in Gurugram, marking its entry into the high-growth preventive healthcare segment. The facility integrates advanced diagnostics like 1.5T MRI and genetic testing with AI-driven insights to offer personalized health programs. This strategic move aims to transition the company from disease detection to predictive wellness, targeting higher-margin lifestyle disease management. As of March 2025, the company operates 298 labs and over 6,607 service centers, providing a strong foundation for scaling such premium initiatives.
Key Highlights
Launched SOVAAKA in Gurugram, a next-generation wellness center blending science and AI technology.
Equipped with high-end diagnostic tools including 1.5T MRI, low-dose CT, and DEXA scanning.
Offers specialized, doctor-designed programs like Eterna for women and Vita for men.
Strategic focus on the growing preventive health market to address rising Non-Communicable Diseases.
Company network includes 298 clinical labs and 12,365 pick-up points as of March 31, 2025.
👀 What to Watch
This expansion into premium wellness is a positive move to increase average revenue per patient; investors should watch for further rollouts of this format in other metros.
Kalpataru Ltd Seeks Shareholder Approval for Material Related Party Transactions
Kalpataru Limited has issued a postal ballot notice to seek shareholder approval for several material related party transactions (RPTs). The proposed resolutions include transactions with its subsidiaries, Kalpataru Properties (Thane) and Agile Real Estate Dev, as well as various promoter group entities and the Managing Director, Mr. Parag M. Munot. Notably, one resolution involves providing financial assistance via Inter Corporate Deposits to its subsidiary, Agile Real Estate Dev. The e-voting period is set for January 03 to February 01, 2026, with results to be announced by February 03, 2026.
Key Highlights
Postal ballot notice dispatched on January 02, 2026, for three ordinary resolutions regarding material RPTs.
Resolution 2 specifically seeks approval for extending financial assistance via Inter Corporate Deposits to subsidiary Agile Real Estate Dev.
Resolution 3 involves transactions with multiple promoter group entities and the Managing Director, Mr. Parag M. Munot.
The remote e-voting window is open for 30 days, starting January 03, 2026, and concluding on February 01, 2026.
The cut-off date for determining shareholder eligibility for voting was Friday, December 26, 2025.
👀 What to Watch
Investors should carefully review the explanatory statement in the postal ballot notice to assess the terms and arm's-length nature of these transactions, particularly the financial assistance to subsidiaries. Monitor the voting results on February 03, 2026, as these transactions can impact the company's cash flow and governance profile.
Kalpataru Ltd Receives ₹80.71 Crore GST Tax Demand and Penalty Order
Kalpataru Limited has received a formal tax demand order (DRC-07) from the CGST Mumbai authorities totaling ₹80.71 crores. The demand relates to alleged non-payment of GST on flats allotted to society members in exchange for development rights during FY 2018-19. The total amount includes ₹40.36 crores in tax and an equivalent ₹40.36 crores in penalties. The company plans to appeal the order and currently expects no material financial impact.
Key Highlights
Total tax demand and penalty amounting to ₹80,71,45,860.
Demand includes ₹40.36 crore in tax and ₹40.36 crore in penalties under Section 74 of the GST Act.
The dispute involves GST on flats provided to members for transfer of development rights in FY 2018-19.
The company intends to challenge the order before the Appellate Authority.
This matter was previously disclosed in the company's Red Herring Prospectus dated June 18, 2025.
👀 What to Watch
Investors should monitor the progress of the appeal as an adverse final ruling could impact the company's cash flows, though the issue was previously disclosed in IPO documents.
Dr. Lal Path Labs Allots 8.37 Crore Bonus Shares in 1:1 Ratio
Dr. Lal Path Labs has completed the allotment of 8,37,75,510 bonus equity shares to eligible shareholders following its 1:1 bonus issue. The allotment was approved via a circular resolution on December 22, 2025, for shareholders on record as of December 19, 2025. This move doubles the company's total number of outstanding shares to 16,75,51,020. The paid-up equity share capital now stands increased at INR 167.55 crore, with the new shares ranking pari-passu with existing ones.
Key Highlights
Allotment of 8,37,75,510 fully paid-up bonus equity shares of face value INR 10 each.
Bonus issue executed in a 1:1 ratio for shareholders as of the December 19, 2025 record date.
Total paid-up equity capital increased from INR 83.77 crore to INR 167.55 crore.
Total number of equity shares outstanding increased to 16,75,51,020 shares.
New bonus shares rank pari-passu in all respects with existing equity shares.
👀 What to Watch
Investors should note that while the number of shares in their portfolio has doubled, the stock price has been adjusted proportionally. No further action is required as the allotment is automatic for eligible shareholders.
Dr. Lal Path Labs Sets Dec 19 as Record Date for 1:1 Bonus Issue
Dr. Lal Path Labs Ltd. has officially fixed Friday, December 19, 2025, as the record date for its 1:1 bonus share issue. Eligible shareholders will receive one new fully paid-up equity share of INR 10 for every one existing share held. The deemed date for the allotment of these bonus shares is scheduled for December 22, 2025. This corporate action follows the approval previously granted by the company's members on December 08, 2025.
Key Highlights
Bonus issue ratio confirmed at 1:1 (one new share for every one existing share).
Record date for determining shareholder eligibility is December 19, 2025.
Deemed date of allotment for the bonus equity shares is December 22, 2025.
The face value of the equity shares remains unchanged at INR 10 per share.
👀 What to Watch
Investors should note that the stock price will adjust downward on the ex-bonus date to reflect the 1:1 ratio, while their total shareholding will double. To be eligible for the bonus, shares must be purchased before the ex-date.
Kalpataru Limited Withdraws Demerger Scheme for Project Yoganand
Kalpataru Limited has officially withdrawn its proposed Scheme of Arrangement for the demerger of Project Yoganand, located in Borivali, Mumbai. The project was initially intended to be transferred to its wholly-owned subsidiary, Kalpataru Residency Private Limited. The National Company Law Tribunal (NCLT), Mumbai Bench, has formally allowed this withdrawal as per its order dated November 25, 2025. This decision reverses the previous board approval, meaning the specific real estate asset will remain within the main listed entity's direct portfolio.
Key Highlights
Withdrawal of demerger scheme for Project Yoganand situated at Borivali, Mumbai
NCLT Mumbai Bench allowed the withdrawal of the application via order dated Nov 25, 2025
The project will no longer be transferred to the subsidiary Kalpataru Residency Private Limited
The Board of Directors had previously approved the withdrawal of the scheme on Nov 10, 2025
👀 What to Watch
Investors should note that the asset remains with the parent company, maintaining the status quo on the balance sheet. Monitor for management commentary regarding the change in corporate restructuring strategy.
Dr. Lal PathLabs Q2 FY26 Net Profit Rises 16.4% YoY to ₹152 Cr; 1:1 Bonus Issue Approved
Dr. Lal PathLabs reported a steady performance for Q2 FY26, with revenue from operations growing 10.7% YoY to ₹730.6 crore. Net profit for the quarter increased by 16.4% YoY to ₹152.2 crore, supported by a 10.8% growth in H1 revenue reaching ₹1,400.4 crore. The company's board has approved a 1:1 bonus issue and a second interim dividend of ₹7 per share, reflecting strong cash flows and management confidence. Operational highlights include the successful integration of Suburban Diagnostics' business into the parent entity following its voluntary liquidation.
Key Highlights
Revenue from operations increased 10.7% YoY to ₹7,306 million in Q2 FY26.
Consolidated Net Profit rose 16.4% YoY to ₹1,522 million compared to ₹1,308 million in the previous year.
Board approved a 1:1 bonus issue (one bonus share for every one share held) subject to shareholder approval.
Declared a second interim dividend of ₹7 per equity share for FY26.
Basic Earnings Per Share (EPS) improved to ₹18.05 from ₹15.52 in the same quarter last year.
👀 What to Watch
The consistent double-digit growth in profit and the announcement of a 1:1 bonus issue are strong positive signals for long-term investors. Maintain a positive outlook on the stock while monitoring the integration benefits of the Suburban Diagnostics business.
Dr. Lal PathLabs Increases Authorized Share Capital to INR 200 Crore
Dr. Lal PathLabs has received shareholder approval via postal ballot to significantly increase its authorized share capital. The limit has been raised from INR 107.96 crore to INR 200 crore, effectively doubling the company's capacity to issue new equity. This change involves a formal amendment to Clause V of the Memorandum of Association. While this is a regulatory enabling provision, it often serves as a precursor to future corporate actions such as bonus issues, rights issues, or equity-based fundraising.
Key Highlights
Authorized share capital increased from INR 107.96 crore to INR 200 crore.
Shareholder approval was obtained through a postal ballot concluded on December 07, 2025.
The new capital structure consists of 20,00,00,000 equity shares with a face value of INR 10 each.
Amendment to Clause V of the Memorandum of Association (MOA) has been officially implemented.
👀 What to Watch
Investors should monitor the company for upcoming announcements regarding bonus issues or capital raises, as this move creates the necessary legal headroom for such actions.
Dr. Lal PathLabs Shareholders Approve Bonus Issue and New 2025 Employee Stock Unit Plan
Dr. Lal PathLabs has announced the successful passage of seven resolutions via postal ballot, most notably the issuance of bonus equity shares and an increase in authorized share capital. The 'Employee Restricted Stock Unit Plan 2025' was approved with 79.81% favor, although it faced significant institutional dissent with 51.5% of institutional votes cast against it. Additionally, shareholders cleared the path for secondary share acquisitions through a trust and a reduction in the 2022 options reserve. These approvals facilitate the company's capital restructuring and long-term incentive programs.
Key Highlights
Bonus Equity Shares issuance approved with 98.04% of total votes in favor.
Increase in Authorized Share Capital passed with a near-unanimous 99.84% majority.
New 'Employee Restricted Stock Unit Plan 2025' secured 79.81% support despite 51.5% institutional pushback.
Secondary acquisition of shares through a Trust route for ESOP implementation approved by 83.76% of voters.
Reduction of Options Reserve under the 2022 ESOP plan approved with 86.80% majority.
👀 What to Watch
Investors should view the bonus issue as a positive move for share liquidity, though the high institutional dissent on the new ESOP plan suggests a need to monitor future management compensation and dilution.
Shalimar Paints Q2 Net Loss Narrows to ₹13.87 Cr; Revenue Dips 8.7% YoY
Shalimar Paints reported a narrowing of its standalone net loss to ₹13.87 crore for the quarter ended September 30, 2025, compared to a loss of ₹19.60 crore in the same period last year. Revenue from operations saw a year-on-year decline of 8.7%, falling to ₹132.11 crore from ₹144.74 crore. Despite the revenue dip, the company showed operational improvement in H1 FY26, with losses reducing to ₹30.53 crore from ₹46.62 crore and a significant improvement in operating cash flows.
Key Highlights
Q2 FY26 revenue decreased 8.7% YoY to ₹132.11 crore from ₹144.74 crore.
Standalone net loss narrowed to ₹13.87 crore in Q2 FY26 vs ₹19.60 crore in Q2 FY25.
H1 FY26 net loss improved to ₹30.53 crore from ₹46.62 crore in H1 FY25, a 34.5% reduction.
Operating cash flow usage reduced drastically to ₹2.25 crore in H1 FY26 from ₹74.60 crore in H1 FY25.
Finance costs increased to ₹12.64 crore for H1 FY26 compared to ₹7.21 crore in H1 FY25.
👀 What to Watch
Investors should monitor the company's ability to reverse the revenue decline while continuing to narrow losses; the significant improvement in cash flow is a positive sign of operational stabilization.
